Gastric cancer (GC) remains a global health burden. While international guidelines share consensus, variations exist in disputed issues. The 2025 Taiwan Consensus and Management Guidelines for Gastric Cancer had just been released. We compared the key recommendations with established international guidelines. A multidisciplinary taskforce addressed key questions and recommendations using modified Delphi method and evidence-based approaches. The comparative review aimed to elucidate similarities and differences among guidelines from Taiwan, Japan, South Korea, China, Europe, and the US. Guidelines converge on absolute endoscopic resection criteria for early GC but differ in extended indications and perioperative approaches for locally advanced disease. Heterogeneity exists in biomarker assessment protocols, cutoff thresholds, and companion diagnostics. For metastatic disease, consensus exists on anti-HER2, anti-VEGF, immunotherapy, and biomarker-driven strategies, though oligo-metastatic definitions and intraperitoneal chemotherapy indications remain controversial. Optimal GC management requires integrating global evidence with regional contexts. The comparative review addresses heterogeneity among international guidelines, which helps harmonize management strategies as therapeutic standards evolve.
Large language models (LLMs) show promise in medical applications, yet their translation into clinical practice requires rigorous validation. Current robustness testing often employs adversarial approaches borrowed from AI safety, raising questions about their alignment with authentic clinical scenarios. To systematically map methodologies used for robustness testing of LLMs in medical contexts and assess their clinical plausibility. A scoping review was conducted following PRISMA-ScR guidelines, searching PubMed, Embase, Web of Science, IEEE Xplore, ACM Digital Library, arXiv, and MedRxiv from January 2023 to September 2025. Two independent physician reviewers screened 5,331 articles, extracting data on testing methodologies, medical domains, expert involvement, and clinical plausibility. Thirty-three studies met inclusion criteria, predominantly from 2025 (82
Bronchiectasis has traditionally been characterized as a neutrophil-driven disease, yet emerging evidence suggested inflammatory heterogeneities. The prognostic significance of elevated serum immunoglobulin E (IgE) in patients without peripheral eosinophilia remains unclear. We conducted a multicenter prospective cohort study between 2017 and 2020 across 16 institutions in Taiwan. Individuals with bronchiectasis but without allergic bronchopulmonary aspergillosis were included. Patients were stratified by baseline absolute eosinophil count (cutoff 300 /uL) and serum IgE level (≤ 100, 100–500, > 500 IU/mL). The primary endpoint was severe exacerbations resulting in hospitalization at one year. Secondary endpoints included all-cause mortality, distribution of sputum pathogen, imaging pattern, and lung function. A total of 579 individuals were enrolled. Nontuberculous mycobacteria (10.7
Transarterial microembolization targets periarticular neovascularization in localized joint pain that persists despite systemic therapy. We report a 31-year-old woman with rheumatoid arthritis involving the elbow, knee, and ankle. The patient underwent selective transarterial microembolization, with intra-arterial imipenem/cilastatin delivered to angiographically identified neovessels. Post-embolization angiography demonstrated decreased hypervascularity. Over 12 months, pain and function improved, and magnetic resonance imaging showed reduced synovial proliferation, periarticular edema, and bone marrow edema. The systemic therapy regimen was maintained unchanged during follow-up. Adverse events were transient and limited to brief procedure-related pain and localized skin discoloration. These observations are hypothesis-generating and support prospective evaluation of TAME as a localized adjunct to systemic immunomodulation.
To evaluate the efficiency, predictability, and residual astigmatism between first- and second-generation keratorefractive lenticule extraction (KLEx) surgeries in a prominent astigmatism population. A retrospective cohort study was conducted, and individuals who underwent first- and second-generation KLEx surgeries were enrolled. A total of 31 and 35 eyes were categorized into first and second KLEx groups, respectively. Visual acuity, refraction, topographic parameters, and surgical indices were recorded. Independent t tests were used to compare the postoperative uncorrected distance visual acuity (UDVA), spherical equivalent (SE), and residual astigmatism between the two groups. The difference in UDVA was not significant three months after KLEx surgery (P = 0.509), and the SEs three months after surgery also presented similar values between the two groups (P = 0.552). The first KLEx group demonstrated greater residual astigmatism than did the second KLEx group throughout the three-month follow-up period (all P < 0.05). The values of surgically induced astigmatism (SIA), difference vector (DV), magnitude of error (ME) and correction index (CoI) were significantly better in the second KLEx group via vector analysis (all P < 0.05). Old age, high steep keratometry (K), high topographic cylinder, large angle kappa, and a small optic zone were correlated with greater residual astigmatism in the first KLEx group (all P < 0.05), whereas only a small optic zone was significantly correlated with greater residual astigmatism in the second KLEx group (P = 0.047). The second-generation KLEx is correlated with a lower risk of residual astigmatism.
